Janet Woodcock, Director of the Center for Drug Evaluation and Research at FDA, speaks during the Reuters Health Summit in New York, May 9, 2011. Credit: Reuters/Brendan McDermid By Debra Sherman ATLANTA | Sat Apr 21, 2012 8:09pm EDT ATLANTA (Reuters) - The U.S. Food and Drug Administration said on Saturday it now spends as much effort and resources on surveilling a drug after it is approved as it does in the pre-approval process. The ...
<< MORE >>